Clinical diagnostics company Verici Dx plc (AIM: VRCI) announced on Wednesday that it has successfully completed a global licensing and commercialisation agreement with Thermo Fisher Scientific.

Thermo Fisher has formally launched its One Lambda Pre-Transplant Risk Assessment (PTRA) Assay, using Verici's pre-transplant prognostic testing technology, at its CLIA facility in Fishers, Indiana.

This agreement, initially announced on 15 November 2023, marks a significant milestone for both companies.

Verici Dx specialises in advanced clinical diagnostics for organ transplants, focusing on kidney transplants. The company's technology uses artificial intelligence-assisted transcriptomic analysis to provide RNA signatures that assess immune response and other critical biological pathways. This approach helps predict risks of injury, rejection and graft failure from pre-transplant to late stages, aiming to improve patient outcomes.

The company is committed to accelerating innovation through research and collaboration with partners in medical devices, biopharmaceuticals and data science. This mission is underpinned by a deep understanding of cell-mediated immunity and access to collaborative studies in kidney transplant cohorts.